A phase II study of buparlisib in relapsed or refractory thymomas.

MLA

Zaid, Mohammad I.Abu, et al. “A Phase II Study of Buparlisib in Relapsed or Refractory Thymomas.” Frontiers in Oncology, vol. 12, Oct. 2022, pp. 1–9. EBSCOhost, https://doi.org/10.3389/fonc.2022.891383.

APA

Zaid, M. I. A., Radovich, M., Althouse, S., Hao Liu, Spittler, A. J., Solzak, J., Badve, S., & Loehrer Sr, P. J. (2022). A phase II study of buparlisib in relapsed or refractory thymomas. Frontiers in Oncology, 12, 1–9. https://doi.org/10.3389/fonc.2022.891383

Chicago

Zaid, Mohammad I. Abu, Milan Radovich, Sandra Althouse, Hao Liu, Aaron J. Spittler, Jeffrey Solzak, Sunil Badve, and Patrick J. Loehrer Sr. 2022. “A Phase II Study of Buparlisib in Relapsed or Refractory Thymomas.” Frontiers in Oncology 12 (October): 1–9. doi:10.3389/fonc.2022.891383.